{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:53:53Z","timestamp":1791374033540,"version":"4.3.1"},"reference-count":22,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Teprotumumab, a monoclonal antibody against the IGF1 receptor, has proven effective in the treatment of thyroid eye disease (TED). Pegvisomant reduces IGF1 levels through selective inhibition of growth hormone receptors. Here, we present a hypothesis-generating case of a 69-year-old patient with progressive TED. Pegvisomant 20 mg was administered daily for 90 days. IGF1 levels declined and remained low\u2013normal during treatment. Clinical activity scores and VISA (vision, inflammation, strabismus and appearance) scores improved rapidly. MRI assessment showed that water content of both extraocular muscles and orbital connective tissue decreased after treatment. 99mTc-DTPA SPECT confirmed the decrease in disease activity. Further studies may confirm the efficacy of pegvisomant in TED.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-pegvisomant-in-severe-treatment-resistant-thyroid-eye-disease-a-case-report<\/jats:p>","DOI":"10.7573\/dic.2026-7-5","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:19:53Z","timestamp":1791371993000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Pegvisomant in severe, treatment-resistant thyroid eye disease: a case report"],"prefix":"10.7573","author":[{"given":"Laura","family":"K\u00f6r\u00f6sk\u00e9nyi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Szkib\u00e1k","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita","family":"Steiber","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Barna","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Nagy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Kar\u00e1nyi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Balla","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Bodor","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endre V","family":"Nagy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annam\u00e1ria","family":"Erdei","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Debrecen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tPerros P, Heged\u00fcs L, Bartalena L, et al. Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12(1):72. https:\/\/doi.org\/10.1186\/s13023-017-0625-1","DOI":"10.1186\/s13023-017-0625-1"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tBurch HB, Sellitti D, Barnes SG, Nagy EV, Bahn RS, Burman KD. Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 1994;78(6):1384\u20131391. https:\/\/doi.org\/10.1210\/jcem.78.6.8200941","DOI":"10.1210\/jcem.78.6.8200941"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tSmith TJ, Heged\u00fcs L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):291\u2013302. https:\/\/doi.org\/10.1016\/j.beem.2011.10.002","DOI":"10.1016\/j.beem.2011.10.002"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tBartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","DOI":"10.1530\/EJE-21-0479"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tBurch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1439\u20131470. https:\/\/ doi.org\/10.1089\/thy.2022.0251","DOI":"10.1089\/thy.2022.0251"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tErdei A, Gazdag A, Bodor M, et al. \u00daj lehet\u0151s\u00e9gek az endokrin orbitopathia kezel\u00e9s\u00e9ben [Novel treatment opportunities in Graves\u2019 orbitopathy]. Orv Hetil. 2014;155(33):1295\u20131300. https:\/\/doi.org\/10.1556\/OH.2014.29963","DOI":"10.1556\/OH.2014.29963"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tErdei A, Paragh G, Kovacs P, et al. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves\u2019 orbitopathy: a five-year follow-up study. Autoimmunity. 2014;47(8):548\u2013 555. https:\/\/doi.org\/10.3109\/08916934.2014.939266","DOI":"10.3109\/08916934.2014.939266"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tDouglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","DOI":"10.1056\/NEJMoa1910434"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tDouglas RS, Couch S, Wester ST, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023;109(1):25\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgad637","DOI":"10.1210\/clinem\/dgad637"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tFleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","DOI":"10.1007\/s11102-020-01091-7"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tThorner MO, Strasburger CJ, Wu Z, et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036- PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab. 1999;84(6):2098\u20132103. https:\/\/doi.org\/10.1210\/jcem.84.6.5732","DOI":"10.1210\/jc.84.6.2098"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tVannucchi G, Campi I, Covelli D, et al. Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid. 2021;31(5):821\u2013828. https:\/\/doi.org\/10.1089\/thy.2020.0269","DOI":"10.1089\/thy.2020.0269"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tChylack LT Jr, Wolfe JK, Singer DM, et al. The lens opacities classification system III. The longitudinal study of Cataract study group. Arch Ophthalmol. 1993;111(6):831\u2013836. https:\/\/doi.org\/10.1001\/archopht.1993.01090060119035","DOI":"10.1001\/archopht.1993.01090060119035"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tMourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73(8):639\u2013 644. https:\/\/doi.org\/10.1136\/bjo.73.8.639","DOI":"10.1136\/bjo.73.8.639"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tDolman PJ. Grading severity and activity in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl. 1):S34\u2013S40. https:\/\/doi.org\/10.1097\/IOP.0000000000001150","DOI":"10.1097\/IOP.0000000000001150"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tHoh HB, Laitt RD, Wakeley C, et al. The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease. Eye. 1994;8(Pt 5):506\u2013510. https:\/\/doi.org\/10.1038\/eye.1994.126","DOI":"10.1038\/eye.1994.126"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tGaluska L, Leovey A, Szucs-Farkas Z, et al. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves\u2019 ophthalmopathy: a comparison with the results from MRI. Nucl Med Commun. 2002;23(12):1211\u20131216. https:\/\/ doi.org\/10.1097\/00006231-200212000-00010","DOI":"10.1097\/00006231-200212000-00010"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tBarnett MJL, Lam J, Jara-Tantoco MN, Casipit C, Eidbo S, Anastasopoulou C. Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study. Endocr Connect. 2025;14(7):e250293. https:\/\/ doi.org\/10.1530\/EC-25-0293","DOI":"10.1530\/EC-25-0293"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tBuchfelder M, van der Lely AJ, Biller BMK, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):419\u2013427. https:\/\/doi.org\/10.1530\/EJE-18-0616","DOI":"10.1530\/EJE-18-0616"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tLeonart LP, Tonin FS, Ferreira VL, Fernandez-Llimos F, Pontarolo R. Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine. 2019;63(1):18\u201326. https:\/\/ doi.org\/10.1007\/s12020-018-1729-7","DOI":"10.1007\/s12020-018-1729-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tP\u00e9rez-Ibave DC, Rodr\u00edguez-S\u00e1nchez IP, Garza-Rodr\u00edguez Mde L, Barrera-Salda\u00f1a HA. Extrapituitary growth hormone synthesis in humans. Growth Horm IGF Res. 2014;24(2\u20133):47\u201353. https:\/\/doi.org\/10.1016\/j.ghir.2014.01.005","DOI":"10.1016\/j.ghir.2014.01.005"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tP\u00e9rez-Ibave DC, Garza-Rodr\u00edguez ML, P\u00e9rez-Maya AA, et al. Expression of growth hormone and growth hormone receptor genes in human eye tissues. Exp Eye Res. 2019;181:61\u201371. https:\/\/doi.org\/10.1016\/j.exer.2019.01.011","DOI":"10.1016\/j.exer.2019.01.011"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/10\/dic.2026-7-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:20:01Z","timestamp":1791372001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/pegvisomant-in-severe-treatment-resistant-thyroid-eye-disease-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-7-5","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"article-number":"dic.2026-7-5"}}